HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prevention of infant eczema by neonatal Bacillus Calmette-Guérin vaccination: The MIS BAIR randomized controlled trial.

AbstractBACKGROUND:
Bacille Calmette-Guérin (BCG) vaccine could play a role in counteracting the rising prevalence of atopic diseases, through its beneficial off-target effects. We aimed to determine whether neonatal BCG vaccination reduces the incidence of eczema in infants.
METHODS:
Randomized controlled trial with 1272 infants allocated to receive BCG-Denmark or no BCG at birth. The primary outcome was the 12-month incidence of eczema based on 3-monthly questionnaires. Eczema was also assessed at a 12-month clinic visit. ClinicalTrial.gov: NCT01906853.
RESULTS:
The 12-month eczema incidence was 32.2% in the BCG group compared with 36.6% in the control group (adjusted risk difference (aRD) -4.3%, 95% CI -9.9% to 1.3%, multiple imputation model). In addition, comparing infants in the BCG group with the control group, 15.7% vs. 19.2% had eczema lesions at the 12-month visit (aRD -3.5%, 95% CI -8.0% to 1.0%); 35.7% vs. 39.0% reported using topical steroids (aRD -3.3, 95% CI -9.2 to 2.7); and 7.3% vs. 10.2% had severe eczema scores (aRD -3.0%, 95% CI -8.8% to 2.7%). In 344 high-risk infants (two atopic parents), the 12-month eczema incidence was 35.3% in the BCG group compared with 46.8% in the control group (aRD -11.5%, 95% CI -21.9% to -1.2%; number needed to treat 8.7, 95% CI 4.6 to 83.3).
CONCLUSION:
There is insufficient evidence to recommend neonatal BCG vaccination in all infants for the prevention of eczema in the first year of life; however, a modest beneficial effect was observed among high-risk infants. A single dose of BCG-Denmark soon after birth could reduce the incidence of eczema in infants with two atopic parents.
AuthorsLaure F Pittet, Nicole L Messina, Kaya Gardiner, Bridget Freyne, Veronica Abruzzo, Kate L Francis, Clare Morrison, Christel Zufferey, Peter Vuillermin, Katrina J Allen, Anne-Louise Ponsonby, Roy Robins-Browne, Frank Shann, Katie L Flanagan, Rod Phillips, Susan Donath, Dan Casalaz, Nigel Curtis
JournalAllergy (Allergy) Vol. 77 Issue 3 Pg. 956-965 (03 2022) ISSN: 1398-9995 [Electronic] Denmark
PMID34309859 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Chemical References
  • BCG Vaccine
Topics
  • BCG Vaccine
  • Dermatitis, Atopic (epidemiology, prevention & control)
  • Eczema (epidemiology, prevention & control)
  • Humans
  • Infant
  • Infant, Newborn
  • Prevalence
  • Vaccination

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: